Extracorporeal cardiopulmonary resuscitation (ECPR) has seen a surge in its application for managing refractory cardiac arrest globally. With lives hanging in the balance, the cost-effectiveness of this cutting-edge treatment remains a pivotal issue in the medical community. This exploration into the economic landscape surrounding ECPR seeks to illuminate its financial viability compared with traditional methods. As healthcare systems grapple with resource allocations, understanding the economic dimensions of ECPR is essential in decision-making processes aimed at enhancing patient outcomes.
An Intensive Systematic Review
Researchers conducted a comprehensive evaluation of the economic aspects of ECPR, diving into databases like MEDLINE, EMBASE, and more. The focus remained on the comparison of ECPR’s cost-effectiveness with standard care in adult cardiac arrest cases. By utilizing backward and forward citation tracking, the researchers unearthed relevant studies, further assessed using a trio of checklists to scrutinize quality and report completeness. Costs converted into 2025 US dollars facilitated a clearer comparison across studies.
Varied Results in Cost-Effectiveness
The analysis revealed a mixed bag of results from the 15 included studies. A substantial portion, 12 studies, indicated ECPR’s high probability of being cost-effective. Conversely, one study found a low probability, another suggested potential cost-effectiveness, and one concluded no cost-effectiveness, particularly in acute aortic dissection cases. Incremental cost-effectiveness ratios (ICERs) exhibited a broad spectrum, from $2,564 to $276,307.
Key inferences drawn from the data include:
– ECPR’s cost-effectiveness is highly contingent on methodology, survival projections, and willingness-to-pay thresholds.
– Ten studies confirmed ECPR’s cost-effectiveness at the US willingness to pay threshold.
– Seven studies also found cost-effectiveness viable under alternative thresholds.
The study concludes that ECPR could demonstrate cost-effectiveness in certain contexts, yet significant variability persists across studies. This inconsistency stems largely from differences in analytical methods, assumptions surrounding patient survival rates, and disparate willingness to pay standards. The findings underscore a compelling need for unified reporting standards to streamline economic evaluation for ECPR implementation across varied healthcare settings. As healthcare continues to advance, balanced decision-making embracing both clinical efficacy and economic feasibility becomes imperative to optimize healthcare resource distribution efficiently, ultimately improving patient care.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
